APX 801
Alternative Names: APX-801Latest Information Update: 24 Aug 2023
At a glance
- Originator Apexigen
- Developer Pyxis Oncology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 23 Aug 2023 Apexigen has been acquired and merged into Pyxis Oncology
- 03 Aug 2022 9364358: No updates
- 24 Jan 2022 APX 801 is available for licensing as of 24 Jan 2022. https://www.apexigen.com/collaborations/